Advanced search
Publication Cover
Drug Design, Development and Therapy Volume 15, 2021 - Issue
Submit an article Journal homepage
179
Views
2
CrossRef citations to date
0
Altmetric
Original Research

A Validated HPLC-MS/MS Method for Quantification of Methotrexate and Application for Therapeutic Drug Monitoring in Children and Adults with Non-Hodgkin Lymphoma

Zhangying Feng1 Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
,
Jinglin Gao1 Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-4662-2764
ORCID Icon,
Xiaonan Gao1 Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
,
Li Hua1 Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
,
Xuyang Nie1 Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
,
Yaqi Sun1 Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of China
&
Mingxia Wang1 Department of Clinical Pharmacology, The Fourth Hospital of Hebei Medical University, Shijiazhuang, People’s Republic of ChinaCorrespondence[email protected]
 show all
Pages 4575-4583 | Published online: 05 Nov 2021

References

  • LevêqueD, BeckerG. The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics. Expert Opin Drug Saf. 2019;18(11):1009–1015. doi:10.1080/14740338.2019.166239531478396
  • LevêqueD, BeckerG, ToussaintE, et al. Clinical pharmacokinetics of methotrexate in oncology. Int J Pharmacokinet. 2017;2(2):137–147. doi:10.4155/ipk-2016-0022
  • NakanoT, KobayashiR, MatsushimaS, et al. Risk factors for delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia and lymphoma. Int J Hematol. 2021;113(5):744–750. doi:10.1007/s12185-020-03071-w33389654
  • MulderMB, HuismanR, EngelsFK, van der SluisIM, KochBCP. Therapeutic drug monitoring of methotrexate in plasma using ultra high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: necessary after administration of glucarpidase in methotrexate intoxications. Ther Drug Monit. 2018;40(4):383–385. doi:10.1097/FTD.000000000000051529994985
  • De AbreuCC, RosaPC, Alves BdaC, et al. Development and validation of HPLC method to determination of methotrexate in children oncologic patients. Eur Rev Med Pharmacol Sci. 2015;19(8):1373–1380.25967711
  • RenX, WangZ, YunY, et al. Simultaneous quantification of methotrexate and its metabolite 7-hydroxy-methotrexate in human plasma for therapeutic drug monitoring. Int J Anal Chem. 2019;2019:1536532. doi:10.1155/2019/153653230853983
  • ZhaoSS, BichelbergerMA, ColinDY, RobitailleR, PelletierJN, MassonJF. Monitoring methotrexate in clinical samples from cancer patients during chemotherapy with a LSPR-based competitive sensor. Analyst. 2012;137(20):4742–4750. doi:10.1039/c2an35839e22943049
  • ReshetnikA, Scheurig-MuenklerC, van der GietM, TölleM. High-flux hemodialysis after administering high-dose methotrexate in a patient with posttransplant lymphoproliferative disease and impaired renal function. Clin Case Rep. 2015;3(11):932–936. doi:10.1002/ccr3.30226576275
  • FerreriAJ, ReniM, FoppoliM, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised Phase 2 trial. Lancet. 2009;374(9700):1512–1520. doi:10.1016/S0140-6736(09)61416-119767089
  • GallaisF, ObericL, FaguerS, et al. Body surface area dosing of high-dose methotrexate should be reconsidered, particularly in overweight, adult patients. Ther Drug Monit. 2021;43(3):408–415.32925658
  • CerminaraZ, DuffyA, NishiokaJ, TrovatoJ, GilmoreS. A single center retrospective analysis of a protocol for high-dose methotrexate and leucovorin rescue administration. J Oncol Pharm Pract. 2019;25(1):76–84. doi:10.1177/107815521772974428942720
  • HowardSC, McCormickJ, PuiCH, BuddingtonRK, HarveyRD. Preventing and managing toxicities of high-dose methotrexate. Oncologist. 2016;21(12):1471–1482. doi:10.1634/theoncologist.2015-016427496039
  • FDA. Methotrexate Injection, USP drugs[EB/OL]; November 04, 2011 [June 10, 2015]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/011719s117lbl.pdf. Accessed October 19, 2021.
  • BarretoJN, PetersonKT, BarretoEF, et al. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate. Support Care Cancer. 2021;29(9):5293–5301. doi:10.1007/s00520-021-06106-y33661366
  • FDA [Internet]. Guidance for industry: bioanalytical method validation; [cited May 24, 2018]. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm070107.Pdf. Accessed October 19, 2021.
  • Schmidt D, Kristensen K, Schroeder H, et al. Plasma creatinine as predictor of delayed elimination of high-dose methotrexate in childhood acute lymphoblastic leukemia: A Danish population-based study. Pediatr Blood Cancer. 2019;66:e27637. doi:10.1002/pbc.27637
  • LianLJ, LinB, CuiX, et al. Development and validation of UHPLC-MS/MSa. Drug Des Devel Ther. 2020;14:4835–4843. doi:10.2147/DDDT.S271568

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.